Compare Heron Therapeutics Inc (HRTX) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Alliant Energy Corporation — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Alliant Energy Corporation trades at $68.56 (market cap $17.69B). The key difference: Alliant Energy Corporation is far larger — about 279× Heron Therapeutics Inc's market cap, and Alliant Energy Corporation pays a 3.14% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | LNT | |
|---|---|---|
Market Cap | $63.41M | $17.69B |
Sector | Health | Utilities |
52-Week High | $1.49 | $78.03 |
52-Week Low | $0.32 | $63.62 |
Enterprise Value | $161.31M | $29.78B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
LNT trades at $69.37, down 0.22% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of $0.65, beating expectations, and maintains strong fundamentals with 18.45% net income margin and 11.14% ROE. Recent news highlights mixed institutional activity and earnings performance influenced by data center demand and cost pressures.
The outlook is balanced with a consensus price target of $77.67 implying upside, supported by earnings beats and a clean energy investment plan. Risks include rising debt levels, cost inflation, and weather-related volatility. Analyst sentiment is positive with no sell ratings, but technical weakness warrants caution near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
